Cite
HARVARD Citation
Borghaei, H. et al. (2021). Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer. Journal of clinical oncology. 39 (7), pp. 723-733. [Online].